FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034642746> ?p ?o ?g. }

• W2034642746 endingPage "792" @default.
• W2034642746 startingPage "785" @default.
• W2034642746 abstract "The aim of this single-arm, phase II study was to estimate the tumor response rate and safety profile of erlotinib HCl (erlotinib, Tarceva, OSI-774) monotherapy in patients with refractory, recurrent, HER1/EGFR-positive epithelial ovarian tumors, who had failed prior taxane and/or platinum-based chemotherapy. Thirty-four patients received 150 mg erlotinib orally once daily for up to 48 weeks or until disease progression or dose-limiting toxicity. Two patients had partial responses, lasting 8+ and 17 weeks, giving an objective response rate of 6% (95% confidence interval [CI], 0.7-19.7%). Fifteen patients (44%) had stable disease, and 17 patients (50%) had progressive disease. Median overall survival was 8 months (95% CI, 5.7-12.7 months), with a 1-year survival rate of 35.3% (95% CI, 19.8-53.5%). Patients with rash survived significantly longer than those without (P= 0.009), correlating with rash grade. Erlotinib was generally well tolerated. The most frequent erlotinib-related adverse events were rash (68%) and diarrhea (38%). Erlotinib had marginal activity but was generally well tolerated. The safety profile appears more favorable than typically experienced with standard chemotherapeutic agents, which is encouraging in these heavily pretreated patients. Combination of erlotinib with chemotherapy or other targeted agents should be considered." @default.
• W2034642746 created "2016-06-24" @default.
• W2034642746 creator A5048278406 @default.
• W2034642746 creator A5048692133 @default.
• W2034642746 creator A5052405727 @default.
• W2034642746 creator A5057469474 @default.
• W2034642746 creator A5070555068 @default.
• W2034642746 creator A5071585351 @default.
• W2034642746 creator A5074839025 @default.
• W2034642746 date "2005-09-01" @default.
• W2034642746 modified "2023-09-24" @default.
• W2034642746 title "Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study" @default.
• W2034642746 cites W1522554466 @default.
• W2034642746 cites W1983719103 @default.
• W2034642746 cites W1989051196 @default.
• W2034642746 cites W2003418168 @default.
• W2034642746 cites W2051120695 @default.
• W2034642746 cites W2065882404 @default.
• W2034642746 cites W2072218566 @default.
• W2034642746 cites W2086691578 @default.
• W2034642746 cites W2097105130 @default.
• W2034642746 cites W2097777938 @default.
• W2034642746 cites W2109694492 @default.
• W2034642746 cites W2132854807 @default.
• W2034642746 cites W2135836172 @default.
• W2034642746 cites W2141258764 @default.
• W2034642746 cites W2328421677 @default.
• W2034642746 doi "https://doi.org/10.1111/j.1525-1438.2005.00137.x" @default.
• W2034642746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16174225" @default.
• W2034642746 hasPublicationYear "2005" @default.
• W2034642746 type Work @default.
• W2034642746 sameAs 2034642746 @default.
• W2034642746 citedByCount "210" @default.
• W2034642746 countsByYear W20346427462012 @default.
• W2034642746 countsByYear W20346427462013 @default.
• W2034642746 countsByYear W20346427462014 @default.
• W2034642746 countsByYear W20346427462015 @default.
• W2034642746 countsByYear W20346427462016 @default.
• W2034642746 countsByYear W20346427462017 @default.
• W2034642746 countsByYear W20346427462018 @default.
• W2034642746 countsByYear W20346427462019 @default.
• W2034642746 countsByYear W20346427462020 @default.
• W2034642746 countsByYear W20346427462021 @default.
• W2034642746 countsByYear W20346427462022 @default.
• W2034642746 countsByYear W20346427462023 @default.
• W2034642746 crossrefType "journal-article" @default.
• W2034642746 hasAuthorship W2034642746A5048278406 @default.
• W2034642746 hasAuthorship W2034642746A5048692133 @default.
• W2034642746 hasAuthorship W2034642746A5052405727 @default.
• W2034642746 hasAuthorship W2034642746A5057469474 @default.
• W2034642746 hasAuthorship W2034642746A5070555068 @default.
• W2034642746 hasAuthorship W2034642746A5071585351 @default.
• W2034642746 hasAuthorship W2034642746A5074839025 @default.
• W2034642746 hasConcept C121608353 @default.
• W2034642746 hasConcept C126322002 @default.
• W2034642746 hasConcept C143998085 @default.
• W2034642746 hasConcept C197934379 @default.
• W2034642746 hasConcept C2776694085 @default.
• W2034642746 hasConcept C2777511904 @default.
• W2034642746 hasConcept C2778087573 @default.
• W2034642746 hasConcept C2778570526 @default.
• W2034642746 hasConcept C2778820342 @default.
• W2034642746 hasConcept C2779438470 @default.
• W2034642746 hasConcept C2909325608 @default.
• W2034642746 hasConcept C31760486 @default.
• W2034642746 hasConcept C530470458 @default.
• W2034642746 hasConcept C71924100 @default.
• W2034642746 hasConcept C90924648 @default.
• W2034642746 hasConcept C98274493 @default.
• W2034642746 hasConceptScore W2034642746C121608353 @default.
• W2034642746 hasConceptScore W2034642746C126322002 @default.
• W2034642746 hasConceptScore W2034642746C143998085 @default.
• W2034642746 hasConceptScore W2034642746C197934379 @default.
• W2034642746 hasConceptScore W2034642746C2776694085 @default.
• W2034642746 hasConceptScore W2034642746C2777511904 @default.
• W2034642746 hasConceptScore W2034642746C2778087573 @default.
• W2034642746 hasConceptScore W2034642746C2778570526 @default.
• W2034642746 hasConceptScore W2034642746C2778820342 @default.
• W2034642746 hasConceptScore W2034642746C2779438470 @default.
• W2034642746 hasConceptScore W2034642746C2909325608 @default.
• W2034642746 hasConceptScore W2034642746C31760486 @default.
• W2034642746 hasConceptScore W2034642746C530470458 @default.
• W2034642746 hasConceptScore W2034642746C71924100 @default.
• W2034642746 hasConceptScore W2034642746C90924648 @default.
• W2034642746 hasConceptScore W2034642746C98274493 @default.
• W2034642746 hasIssue "5" @default.
• W2034642746 hasLocation W20346427461 @default.
• W2034642746 hasLocation W20346427462 @default.
• W2034642746 hasOpenAccess W2034642746 @default.
• W2034642746 hasPrimaryLocation W20346427461 @default.
• W2034642746 hasRelatedWork W1551013575 @default.
• W2034642746 hasRelatedWork W1667731616 @default.
• W2034642746 hasRelatedWork W1986001758 @default.
• W2034642746 hasRelatedWork W2120200191 @default.
• W2034642746 hasRelatedWork W2122899729 @default.
• W2034642746 hasRelatedWork W2133353215 @default.
• W2034642746 hasRelatedWork W3003805320 @default.
• W2034642746 hasRelatedWork W3031063891 @default.

• next